Abstract:Dong et al. present a novel approach to preoperative lymph node (LN) metastasis evaluation in rectal cancer. By integrating MRI radiomics with clinical data, they developed a machine learning model that surpasses traditional assessment methods in predicting LN metastasis, achieving a higher positive predictive value. The findings suggest that this approach could significantly aid in tailoring more precise treatment strategies, emphasizing the clinical utility of combining radiomics with conventional clinical data. This research exemplifies how precision medicine can enhance non-invasive diagnostic accuracy and assist in tailoring treatment strategies, thus improving management for patients with colorectal cancer.Building upon this theme of innovative diagnostic techniques, O'Shea et al. introduce an advancement in integrating genomic testing into routine oncology practice. Their study presents a model, derived from comprehensive implementation research, provides a structured approach to improve access to genomic testing for Lynch syndrome. By addressing barriers such as funding, infrastructure, and role delineation, and proposing solutions like embedded genetic counselors and electronic medical record integration, this model aims to streamline genetic testing processes. Its successful implementation could serve as a blueprint for other hereditary cancer syndromes, facilitating broader adoption of precision medicine practices. This study aims to integrate precision medicine into routine oncology practice, ensuring that individuals with hereditary risks receive timely and accurate genetic testing and subsequent personalized care.Complementing these advancements in diagnostics and genetic testing, Brand et al. explore the potential of cytokine profiling to predict colorectal cancer risk in Lynch syndrome patients. By analyzing normal-appearing colorectal tissue, the study identifies immune signatures that distinguish LS patients with a history of CRC from those without. These findings suggest that immune microenvironment profiling could become a valuable tool in CRC risk assessment and prevention strategies, enabling more personalized surveillance and intervention approaches.While Brand et al. focus on risk prediction, another crucial aspect of personalized care for hereditary colorectal cancer syndromes is chemoprevention. In this vein, Mraz et al. provide valuable insights into how chemoprevention is widely discussed and applied, particularly in Lynch syndrome (LS) and familial adenomatous polyposis (FAP). There remains considerable variability in the specifics of these practices. Most professionals recommend aspirin for LS patients, albeit with no consensus on the optimal dosage. This heterogeneity underscores the need for standardized guidelines and further research to optimize chemoprevention strategies, considering individual patient factors to maximize benefits and minimize risks.As the field of chemoprevention continues to evolve, so too does our understanding of genetic risk factors. Highlighting this progression, Li et al. demonstrate the critical role of genetic testing in hereditary cancer syndromes through their identification of a novel splicing variant in the MSH2 gene. This study not only confirms the pathogenicity of the MSH2 c.793-1G>A variant through bioinformatics and functional assays but also underscores the importance of regular surveillance for mutation carriers. Such genetic insights are vital for early detection and prevention of CRC in at-risk populations. By confirming the pathogenicity of this variant, this study supports the role of precision medicine in identifying genetic mutations and highlights the need for regular surveillance and personalized risk assessment for mutation carriers.Moving from genetic risk factors to the broader molecular landscape of colorectal cancer, He et al. offer new perspectives on the molecular underpinnings of colon cancer through their exploration of cuproptosis-related genes. By identifying distinct molecular subtypes associated with different tumor microenvironment characteristics and treatment responses, their research contributes to the development of more tailored therapeutic strategies. This study exemplifies how precision medicine can guide the development of personalized treatment options for patients with hereditary predispositions to colon cancer, further emphasizing the importance of molecular profiling in advancing CRC care.These studies collectively underscore the rapidly evolving landscape of CRC diagnosis and treatment, driven by advancements in genomics, radiomics, and immunology. By presenting these diverse contributions, we aim to provide a comprehensive overview of how precision medicine is reshaping our approach to hereditary CRC syndromes. Looking ahead, it will be crucial to continue validating these findings through large-scale, multicenter studies and to develop standardized -Abstract Truncated-

From tumour heterogeneity to advances in precision treatment of colorectal cancer

Molecular subtypes of colorectal cancer in the era of precision oncotherapy: Current inspirations and future challenges

Precision oncology in metastatic colorectal cancer — from biology to medicine

[New progression of translational research on colorectal cancer].

Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines

The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer

Molecular Subtyping of Hepatocellular Carcinoma: A Step Toward Precision Medicine

Molecular Profiling Provides Clinical Insights Into Targeted and Immunotherapies as Well as Colorectal Cancer Prognosis

Exploring the mystery of colon cancer from the perspective of molecular subtypes and treatment

Panomics reveals patient individuality as the major driver of colorectal cancer progression

The progress and controversy on precision medicine of colorectal cancer

Editorial: Hereditary colorectal cancer syndromes and risk assessment in the era of precision medicine

From Subtypes to Solutions: Integrating CMS Classification with Precision Therapeutics in Colorectal Cancer

[Progress of Molecular Subtypes of Colorectal Cancer].

Molecular Testing to Optimize and Personalize Decision Making in the Management of Colorectal Cancer

Future Diagnosis and Treatment of Colorectal Cancer from the View of Precision Medicine

Improving the Value of Molecular Testing: Current Status and Opportunities in Colorectal Cancer Precision Medicine.

Current advances in targeted therapy for metastatic colorectal cancer – Clinical translation and future directions

Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability and CIMP status: Prognostic implications and response to chemotherapy

Clinical management of breast cancer heterogeneity

Heterogeneous clinical and pathological landscapes of HER2 positive colorectal cancer